Impact of ⁶⁸ Gallium prostate-specific membrane antigen tracers on the management of patients with prostate cancer who experience biochemical recurrence.

Abstract

To investigate the impact of ⁶⁸ Gallium prostate-specific membrane antigen (⁶⁸ Ga-PSMA) tracers on the management of prostate cancer (PCa) patients with biochemical recurrence (BCR) by conducting a systematical review and meta-analysis. We performed a literature search of the PubMed, Embase and Web of Science databases up to 29 October 2019. We included studies that reported the proportion of patients whose management changed after ⁶⁸ Ga-PSMA tracers were used in patients with BCR. We used the Quality Assessment of Diagnostic Accuracy Studies-2 tool to evaluate the quality of the included studies. The proportion of patients with management changes were pooled using a random-effects model. Subgroup analyses and meta-regression analyses were performed to explore the source of heterogeneity. A Sankey diagram was used to show treatment change from before to after the use of ⁶⁸ Ga-PSMA tracers. We included 20 eligible studies (2026 patients). The pooled proportion of patients with management change was 53% (95% confidence interval [CI] 46-60) in patients with BCR and 51% (95% CI, 34-67) in patients with early BCR (prostate-specific antigen [PSA] <0.5 ng/mL). The pooled positron-emission tomography-positive rate in patients with BCR was 68% (95% CI 59-78). Fourteen studies reported management change, with most changes being intermodal in nature (42%, vs 17% intramodal change). The use of ⁶⁸ Ga-PSMA tracers altered the management of more than half of PCa patients with BCR, including those with early BCR. ⁶⁸ Ga-PSMA tracers might be used to guide individualized treatment in patients with BCR, particularly those with early BCR.